Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2015; 21(26): 8132-8139
Published online Jul 14, 2015. doi: 10.3748/wjg.v21.i26.8132
Published online Jul 14, 2015. doi: 10.3748/wjg.v21.i26.8132
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication
Jae Jin Hwang, Dong Ho Lee, Ae-Ra Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 463-707, South Korea
Author contributions: Hwang JJ and Lee DH were responsible for the study conception and design, data analysis and interpretation, and manuscript drafting; Lee AR, Yoon H, Shin CM, Park YS and Kim N critically revised the article for important intellectual content; all the authors reviewed and approved the final version to be published.
Institutional review board statement: The study was reviewed and approved by the Seoul National University Bundang Hospital Institutional Review Board.
Informed consent statement: None.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dong Ho Lee, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam, Gyeonggi-do 463-707, South Korea. dhljohn@yahoo.co.kr
Telephone: + 82-31-7877006 Fax: + 82-31-7874051
Received: December 30, 2014
Peer-review started: December 31, 2014
First decision: January 22, 2015
Revised: February 5, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: July 14, 2015
Peer-review started: December 31, 2014
First decision: January 22, 2015
Revised: February 5, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: July 14, 2015
Core Tip
Core tip: This study evaluated the efficacy of 14-d bismuth-based quadruple therapy compared with a corresponding 7-d quadruple therapy as second-line eradication treatment of Helicobacter pylori (H. pylori) infection in South Korea. H. pylori eradication rates in the 14-d treatment group were significantly higher than in the 7-d treatment group for both the intent-to-treat and per-protocol analysis. The high eradication rate, excellent compliance, and safety of the 14-d regimen suggest its potential suitability as a second-line eradication treatment. The 14-d bismuth-based quadruple therapy is a significantly more effective second-line eradication treatment than the 7-d alternative for H. pylori infection in Korean patients.